4'-Hydroxychalcone

4'-Hydroxychalcone

SCHEMBL127606

O=C(C=Cc1ccccc1)c1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1B1 Q16678 10/20 1.00
MAOB P27338 6/20 1.00
MAPT P10636 6/20 1.00
KMT2A Q03164 5/20 1.00
HSPD1 P10809 3/20 1.00
HSPE1 P61604 3/20 1.00
CYP3A4 P08684 2/20 1.00
F3 P13726 2/20 1.00
MAOA P21397 2/20 1.00
MEN1 O00255 2/20 1.00
ALDH2 P05091 1/20 1.00
CYP19A1 P11511 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
RAB9A P51151 4/20 0.86
PKM P14618 1/20 0.86
NFKB1 P19838 1/20 0.86
NFKB2 Q00653 1/20 0.86
RELA Q04206 1/20 0.86
TNFRSF1A P19438 2/20 0.78
PLIN1 O60240 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
4'-Hydroxychalcone SCHEMBL25232573 1.00 CYP1B1 (1.00) CYP1B1MAOBMAPTKMT2AHSPD1
4'-Hydroxychalcone SCHEMBL1373907 1.00 CYP1B1 (1.00) CYP1B1MAOBMAPTKMT2AHSPD1
4,4'-Dihydroxychalcone SCHEMBL20608175 0.96 CYP1B1 (0.93) CYP1B1MAOBMAPTKMT2AHSPD1
4,4'-Dihydroxychalcone SCHEMBL20608174 0.96 CYP1B1 (0.93) CYP1B1MAOBMAPTKMT2AHSPD1
SCHEMBL17061353 0.95 CYP1B1 (0.90) CYP1B1MAOBMAPTKMT2AHSPD1
SCHEMBL25285070 0.95 CYP1B1 (0.90) CYP1B1MAOBMAPTKMT2AHSPD1
SCHEMBL17061354 0.95 CYP1B1 (0.90) CYP1B1MAOBMAPTKMT2AHSPD1
4,4'-Dihydroxychalcone SCHEMBL9542070 0.94 KMT2A (0.96) CYP1B1MAOBMAPTKMT2AHSPD1
4,4'-Dihydroxychalcone SCHEMBL25282681 0.94 KMT2A (0.96) CYP1B1MAOBMAPTKMT2AHSPD1
Chalcone SCHEMBL28414035 0.92 CYP1B1 (0.86) CYP1B1MAOBMAPTKMT2AHSPD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 725 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260096569-A1 EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES APEEL TECH INC (US) 2026-04-09 US claimed
US-20260002134-A1 CHOROID PLEXUS ORGANOIDS AND METHODS FOR PRODUCTION THEREOF UNITED KINGDOM RESEARCH AND INNOVATION (GB) 2026-01-01 US claimed
US-20250092358-A1 In Vitro Breeding Systems and Methods in Livestock ABS GLOBAL, INC. (US) 2025-03-20 US claimed
EP-4346395-A1 IN VITRO BREEDING SYSTEMS AND METHODS IN LIVESTOCK ABS Global, Inc. (US) 2024-04-10 EP claimed
CN-117320559-A Edible coating with antimicrobial properties 阿比尔技术公司 2023-12-29 CN claimed
CN-117142988-A Preparation method and application of diazonaphthoquinone sulfonate monoester compound 安徽觅拓材料科技有限公司 2023-12-01 CN claimed
CN-116376281-A Polyimide material with high solubility and high gas separation performance, and preparation method and application thereof 常州工学院 2023-07-04 CN claimed
US-20230003721-A1 MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2023-01-05 US claimed
WO-2022251549-A1 IN VITRO BREEDING SYSTEMS AND METHODS IN LIVESTOCK ABS GLOBAL, INC. (US) 2022-12-01 WO claimed
US-20220330565-A1 EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES APEEL TECHNOLOGY, INC. 2022-10-20 US claimed
WO-2014143539-A1 COMPOSITION AND METHOD FOR PREVENTING, REDUCING, ALLEVIATING, OR TREATING IDIOPATHIC VOMITING THE IAMS COMPANY (US) 2014-09-18 WO claimed
US-20140271949-A1 Composition and Method for Preventing, Reducing, Alleviating or Treating Idiopathic Vomiting THE IAMS COMPANY (US) 2014-09-18 US claimed
US-20030104145-A1 Chemical adsorbent and liquid crystal alignment layer utilizing the same and liquid crystal display device utilizing the same and methods of manufacturing them MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 2003-06-05 US claimed
US-6495221-B1 EXTREMELY THIN AND TRANSPARENT FILM IN NANOMETER ORDER; HYDROCHALCONE DERIVATIVE SUBSTITUTED WITH A ISOCYANATOSILYL GROUP MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 2002-12-17 US claimed
EP-0962460-A1 CHEMISORPTIVE SUBSTANCE, ALIGNED LIQUID-CRYSTAL FILM AND LIQUID-CRYSTAL DISPLAY ELEMENT BOTH MADE BY USING THE SAME, AND PROCESSES FOR PRODUCING THESE MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 1999-12-08 EP claimed
EP-0528975-A4 GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES 1993-09-15 EP claimed
EP-0528975-A1 GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES BAYLOR COLLEGE OF MEDICINE (US) 1993-03-03 EP claimed
WO-1993001824-A1 COMBINATION THERAPY USING BIOFLAVONOID COMPOUNDS WITH ANTI-CANCER DRUGS BAYLOR COLLEGE OF MEDICINE (US) 1993-02-04 WO claimed
WO-1991017749-A1 GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES BAYLOR COLLEGE OF MEDICINE (US) 1991-11-28 WO claimed
US-4804612-A PLASMA DRY-ETCHING RESISTANCE TOKYO OHKA KOGYO CO., LTD. (JP) 1989-02-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030104145-A1 Chemical adsorbent and liquid crystal alignment layer utilizing the same and liquid crystal display device utilizing the same and methods of manufacturing them UACA, CRYAA, CUTA CYP1B1 2725/4885MAOB 2509/4885MAPT 46/4885
US-20260002134-A1 CHOROID PLEXUS ORGANOIDS AND METHODS FOR PRODUCTION THEREOF BMP4, WNT3A, BMP1 CYP1B1 3775/4885MAOB 4449/4885MAPT 1666/4885
US-20260096569-A1 EDIBLE COATING WITH ANTIMICROBIAL PROPERTIES CYP51A1, ERG28, NISCH CYP1B1 1186/4885MAOB 1312/4885MAPT 4702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.